Single domain antibody capable of being combined with different serotypes of AAV and application of single domain antibody

By developing affinity purification filler formed by coupling single-domain antibodies with high affinity with AAV particles and microspheres, the problem of affinity chromatography media relying on imported products in the industrial production of AAV drugs is solved, and efficient purification and cost reduction of AAV is achieved .

CN118955697AActive Publication Date: 2024-11-15SHANGHAI YAONUO BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411027377.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

In the industrial production of existing AAV drugs, affinity chromatography media relies on imported products, resulting in high costs and unstable delivery times, which brings potential supply cuts to domestic AAV drug companies.

Method used

A single domain antibody with high affinity with different serotype AAV particles was developed to replace traditional imported affinity chromatography media and achieve efficient purification of AAV by coupling with microspheres.

Benefits of technology

This single-domain antibody binds strongly to AAV particles, can be effectively used for AAV affinity purification, reduce production costs, and avoid unstable delivery time problems, providing a reliable domestic purification solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955697A_ABST
    Figure CN118955697A_ABST
Patent Text Reader

Abstract

The invention provides a single-domain antibody capable of being combined with different serotypes of AAVs and application of the single-domain antibody. The single-domain antibody comprises CDR1, CDR2 and CDR3, and amino acid sequences of the CDR1, the CDR2 and the CDR3 are respectively shown as SEQ ID NO.2-4 or mutants of the CDR1, the CDR2 and the CDR3. The single-domain antibody can be combined with various serotypes of AAV, has high affinity activity, and can be used for affinity purification of AAV.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomaterials, and in particular to a single-domain antibody capable of combining with AAVs of different serotypes and uses thereof. Background Art

[0002] Recombinant adeno-associated virus (rAAV) vectors are currently considered to be one of the gene therapy vectors with the most promising clinical application prospects, due to their diverse types, extremely low immunogenicity, high safety, wide range of host cells (capable of infecting both dividing and non-dividing cells), strong diffusion ability, and long gene expression time in vivo. Currently, a variety of drugs based on AAV vectors have been approved for marketing, and a large number of clinical studies are underway.

[0003] In the industrial production of AAV drugs, how to quickly, efficiently and in large quantities purify packaged AAV particles from cell lysis species is one of the key steps to reduce the AAV production cycle and cost. Existing AAV purification processes include density gradient centrifugation, ion exchange chromatography, affinity chromatography, molecular exclusion chromatography, etc. In order to obtain clinical-grade AAV products, a variety of methods are usually combined to obtain high-purity products. Among them, affinity chromatography technology is used by more and more AAV drug companies for its simplicity, rapidity, efficiency and gentleness.

[0004] Affinity chromatography uses a medium (mostly microspheres) with surface coupling that specifically binds to intact AAV particle ligands as the stationary phase. When the cell lysate containing AAV particles flows through the stationary phase, the AAV particles bind to the affinity ligands on the stationary phase, thereby purifying and concentrating the AAV. However, the affinity chromatography media currently used in the industrial production of AAV are all imported products, such as Cytiva's Capto AVB purification filler, ThermoFisher's POROS CaptureSelect AAV8, AAV9 and AAVX purification fillers, and Repligen's AVIpure purification filler. These imported products are expensive and have unstable delivery times, which poses a potential risk of supply interruption to domestic AAV drug companies. They are a key factor in the industrial production of AAV, and breakthroughs in this field are urgently needed.

[0005] Based on the above problems, the present invention provides a single-domain antibody, which has a high affinity for AAV particles of various serotypes and has good application prospects in AAV affinity purification. Summary of the invention

[0006] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a single-domain antibody that can bind to different serotypes of AAV and its use, so as to solve the problem of difficulty in purifying AAV in the prior art.

[0007] To achieve the above-mentioned object and other related objects, the present invention provides a single-domain antibody, comprising CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 is as shown in SEQ ID NO:2, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, or 95% functional identity; the amino acid sequence of CDR2 is as shown in SEQ ID NO:3, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, or 95% functional identity; the amino acid sequence of CDR3 is as shown in SEQ ID NO:4, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, or 95% functional identity.

[0008] The mutants may be the following:

[0009] The amino acid sequence of the CDR1 is shown in SEQ ID NO: 21; the amino acid sequence of the variable region is shown in SEQ ID NO: 35;

[0010] The amino acid sequence of the CDR2 is shown in SEQ ID NO:30; the amino acid sequence of the variable region is shown in SEQ ID NO:43;

[0011] The amino acid sequence of the CDR3 is shown in SEQ ID NO:39; the amino acid sequence of the variable region is shown in SEQ ID NO:51;

[0012] The amino acid sequence of the CDR1 is shown as SEQ ID NO:45, the amino acid sequence of the CDR1 is shown as SEQ ID NO:46; the amino acid sequence of the CDR1 is shown as SEQ ID NO:47; at this time, the amino acid sequence of the variable region is shown as SEQ ID NO:44.

[0013] Furthermore, the single-domain antibody also includes a framework region FR1 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:5.

[0014] Furthermore, the single-domain antibody also includes a framework region FR2 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:6.

[0015] Furthermore, the single-domain antibody also includes a framework region FR3 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:7.

[0016] Furthermore, the single-domain antibody also includes a framework region FR4 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:8.

[0017] Furthermore, the amino acid sequence of the single domain antibody is shown in SEQ ID NO.1.

[0018] Another aspect of the present invention provides a gene encoding the above-mentioned single domain antibody.

[0019] Furthermore, the nucleotide sequence of the gene is shown in SEQ ID NO.16.

[0020] Another aspect of the present invention provides a vector, wherein the vector contains or has the above gene inserted therein.

[0021] Furthermore, the vector may be pET-22b(+).

[0022] Another aspect of the present invention provides a cell, wherein the cell contains the above-mentioned vector.

[0023] Furthermore, the cell may be Escherichia coli.

[0024] Another aspect of the present invention provides the use of the single domain antibody for purifying AAV. The AAV can be a common species, such as AAV2, AAV5, AAV6 and AAV8.

[0025] Another aspect of the present invention provides a filler for purifying AAV, wherein the filler contains the above-mentioned single domain antibody. The product may be a resin filler.

[0026] Furthermore, the single domain antibody is coupled to a microsphere. The microsphere may be a microsphere made of agarose gel. Such microspheres can generally be used for affinity purification of AVV. Those skilled in the art can purchase them from the market.

[0027] As described above, the single domain antibody of the present invention that can bind to different serotypes of AAV has the following beneficial effects:

[0028] It can bind to various serotypes of AAV and has high affinity activity. It can be used for affinity purification of AAV. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Agarose gel electrophoresis of PCR amplification of inserted gene. Lane M: DNA Marker; Lane 1-2: PCR amplification product.

[0030] Figure 2 Agarose gel electrophoresis of bacterial liquid PCR identification. Lane M: DNA Marker; Lanes 1-8: PCR amplification products of bacterial liquid.

[0031] Figure 3 Agarose gel electrophoresis of empty vector digestion. Lane M: DNA Marker; Lane 1: pET-22b(+) empty vector digestion product.

[0032] Figure 4 Agarose gel electrophoresis of recombinant plasmid digestion. Lane M: DNA Marker; Lane 1: pET-22b(+) plasmid; Lane 2: ApaI-XhoI digestion product of pET-22b(+).

[0033] Figure 5 Map of the pET-22b(+) plasmid with the single domain antibody gene sequence inserted.

[0034] Figure 6 Sequencing results of pET-22b(+) plasmid with inserted single domain antibody gene sequence.

[0035] Figure 7 Gel electrophoresis diagram of expression identification results. Lane M: protein marker; Lane 1: uninduced sample; Lanes 2-6: induced samples.

[0036] Figure 8 Gel electrophoresis plots of optimization and solubility analysis results. Lane M: protein marker; Lane 1: sample induced by 0.2mM IPTG at 15℃; Lane 2: sample induced by 1.0mM IPTG at 15℃; Lane 3: sample induced by 0.2mM IPTG at 37℃; Lane 4: sample induced by 1.0mM IPTG at 37℃; Lane 5: uninduced sample; Lane 6: precipitate sample induced by 1.0mM IPTG at 37℃; Lane 7: supernatant sample induced by 1.0mM IPTG at 37℃; Lane 8: precipitate sample induced by 0.2mM IPTG at 37℃; Lane 9: supernatant sample induced by 0.2mM IPTG at 37℃; Lane 10: precipitate sample induced by 1.0mM IPTG at 15℃; Lane 11: supernatant sample induced by 1.0mM IPTG at 15℃; Lane 12: precipitate sample induced by 0.2mM IPTG at 15℃; Lane 13: precipitate sample induced by 0.2mM IPTG at 15℃ Supernatant sample after IPTG induction.

[0037] Fig. 9 Affinity purification SDS-PAGE results. Lane M: protein marker; Lane 1: precipitate after fragmentation; Lane 2: supernatant after fragmentation; Lane 3: effluent; Lane 4: washing sample; Lane 5: elution sample.

[0038] Fig.10 Protein dialysis SDS-PAGE results. Lane M: protein marker; Lane S: dialyzed sample.

[0039] Fig.11 Protein purification SDS-PAGE results. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0040] Fig.12 . Analysis curve of single domain antibody binding activity to AAV2 ELISA.

[0041] Fig.13 .Analysis curve of single domain antibody binding activity to AAV5 ELISA.

[0042] Fig.14 . Analysis curve of single domain antibody binding activity to AAV6 ELISA.

[0043] Fig.15 .Analysis curve of single domain antibody binding activity to AAV8 ELISA.

[0044] Fig.16 . Analysis curve of single domain antibody binding activity to AAV2 ELISA.

[0045] Fig.17 .Analysis curve of single domain antibody binding activity to AAV5 ELISA.

[0046] Fig.18 . Analysis curve of single domain antibody binding activity to AAV6 ELISA.

[0047] Fig.19 .Analysis curve of single domain antibody binding activity to AAV8 ELISA.

[0048] Fig. 20 .Affinity purification chromatogram of AAV5 dynamic loading using single domain antibody affinity medium.

[0049] Fig.21 .Silver staining detection after affinity purification of AAV2 dynamic loading by single domain antibody affinity filler. Lane 1: protein marker; Lane 2: AAV2 crude extract; Lane 3: flow-through; Lane 4: eluate; Lane 5: protein marker

[0050] Fig. 22 Silver staining detection after affinity purification of AAV5 dynamic loading by single domain antibody affinity filler. Lane 1: protein marker; Lane 2: AAV5 crude extract; Lane 3: flow-through; Lane 4: eluate; Lane 5: protein marker.

[0051] Fig.23Silver staining detection after affinity purification of AAV8 dynamic loading by single domain antibody affinity filler. Lane 1: protein marker; Lane 2: AAV8 crude extract; Lane 3: flow-through; Lane 4: eluate; Lane 5: marker.

[0052] Fig.24 . SDS-PAGE results of G30A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0053] Fig.25 . SDS-PAGE results of S56T protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0054] Fig.26 . SDS-PAGE results of G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0055] Fig. 27 . SDS-PAGE results of G30A / S56T / G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0056] Fig.28 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV2 ELISA.

[0057] Fig.29 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV5 ELISA.

[0058] Fig.30 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV6 ELISA.

[0059] Fig.31 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV8 ELISA. DETAILED DESCRIPTION

[0060] The term "single domain antibody" has the ordinary meaning in the art and refers to a single heavy chain variable domain of an antibody type that can be found in camelid mammals that is naturally free of light chains. The amino acid sequence and structure of a single domain antibody can be considered to consist of four framework regions or "FRs", which are referred to in the prior art and herein as "framework region 1" or "FR1"; "framework region 2" or "FR2"; "framework region 3" or "FR3"; "framework region 4" or "FR4", respectively, and the framework regions are separated by three complementary determining regions or "CDRs", which are referred to in the prior art as "complementary determining region 1" or "CDR1"; "complementary determining region 2" or "CDR2" and "complementary determining region 3" or "CDR3". Therefore, a single domain antibody can be defined as an amino acid sequence having the following general structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1 to FR4 refer to framework regions 1-4, respectively, and CDR1 to CDR3 refer to complementary determining regions 1-3, respectively. In the context of the present invention, the amino acid residues of a single domain antibody are numbered according to the general code of the VH domain given by the IMGT numbering system. The results of the kabat rule numbering are also shown below. However, in order to avoid ambiguity, the IMGT numbering system is mainly used herein.

[0061] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0062] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0063] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0064] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields.

[0065] Example 1 Single domain antibody variable region sequence

[0066] 1. Single domain antibody variable region sequence:

[0067] QVQLQESGGGLVQAGGSLRLSCAASGRTHGMYAMGWFRQAPGKEREFVAVQDLTASNTHYSSAVKGRFTISSRDNAK NTAYLQMNNLKPEDTAVYYCAAGPTIMSGSYNSARDYDYWGQGTQVTVSS(SEQ ID NO.1)

[0068] 1.1 IMGT Rule Number

[0069] The CDR1 sequence is GRTHGMYA (SEQ ID NO. 2)

[0070] The CDR2 sequence is QDLTASNT (SEQ ID NO. 3)

[0071] The CDR3 sequence is AAGPTIMSGSYNSARDYDY (SEQ ID NO. 4)

[0072] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 5)

[0073] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO.6)

[0074] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO.7)

[0075] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.8)

[0076] 1.2 Kabat rule number

[0077] The CDR1 sequence is MYAMG (SEQ ID NO.9)

[0078] The CDR2 sequence is VQDLTASNTHYSSAVKG (SEQ ID NO. 10)

[0079] The CDR3 sequence is GPTIMSGSYNSARDYDY (SEQ ID NO. 11)

[0080] FR1 sequence is QVQLQESGGGLVQAGGSLRLSCAASGRTHG (SEQ ID NO. 12)

[0081] FR2 sequence is WFRQAPGKEREFVA (SEQ ID NO. 13)

[0082] FR3 sequence is RFTISRDNAKNTAYLQMNNLKPEDTAVYYCAA (SEQ ID NO. 14)

[0083] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.15)

[0084] Example 2 Expression and purification of single domain antibodies in E. coli

[0085] We expressed the screened single domain antibodies in eukaryotic and prokaryotic systems and then purified them.

[0086] 2.1 Plasmid construction, transformation and identification

[0087] 2.1.1 Plasmid construction

[0088] The nucleotide sequence of the target gene is as follows (SEQ ID NO.16):

[0089] CAGGTGCAGCTGCAGGAAAGCGGCGGTGGTCTGGTTCAGGCAGGTGGTAGTTCTGCGCC

[0090] TGAGTTGTGCCGCAAGTGGCCGTACCCATGGTATGTATGCAATGGGTTGGTTTCGTCAGG

[0091] CACCGGGTAAAGAACGCGAATTTGTGGCCGTGCAGGATCTGACCGCCAGCAATACCCCAT

[0092] TATAGCAGTGCCGTGAAAGGTCGCTTTACCATTAGTCGTGATAATGCCAAAAATACCGCC

[0093] TATCTGCAGATGAATAATCTGAAACCGGAAGATACCGCCGTTTATTATTGCGCAGCCGGC

[0094] CCGACCATTATGAGCGGTAGTTATAATAGCGCACGTGATTATGATTATTGGGGCCAGGGTACCCAGGTTACCGTTAGTAGCGCAGCCCCGGGCTGC.

[0095] The primers of the single-domain antibody target gene sequence were amplified by PCR to obtain a fragment PCR product, which was recombined into the target vector pET-22b(+) (NdeI, XhoI restriction vector) by multi-segment recombination to obtain a full-length construct. The connection method is as follows. The processed target fragment and vector connection reaction system

[0096]

[0097]

[0098] 2.1.2 Plasmid transformation

[0099] a. Add 1 μl of plasmid to 100 μl of competent cells, gently shake and rotate to mix, and place on ice for 3 minutes;

[0100] b. 42℃ water bath for 90s;

[0101] c. Place in ice bath for 3 minutes;

[0102] d. Add 800 μl of 37°C pre-warmed LB medium to each tube and shake gently at 200 rpm at 37°C for 40 minutes.

[0103] 2.1.3 Verification of recombinants

[0104] a. Prepare agar plates containing corresponding resistance;

[0105] b. Take 100 μl of bacterial solution and add it to the agar plate containing the corresponding resistance. Use a sterile glass applicator to gently spread the bacteria on the surface of the plate and incubate the plate at 37°C for 15 minutes.

[0106] c. Invert the plate and incubate at 37°C for 12-16 hours;

[0107] d. Pick bacteria from the plate and shake at 37℃ and 250 rpm for 14 hours. Perform PCR identification on the bacterial solution and send the positive clone solution for sequencing.

[0108] 2.1.4 Verification of cloned plasmids

[0109] Upstream primer:

[0110] AATTTTGTTTAACTTTAAGAAGGAGATATACATATGCATCATCATCACCATCAGGT TCAG(SEQID NO.17)

[0111] Downstream primer: AGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTTAACAACCCGGGGCTGCACTACTCACGGTCACCT (SEQ ID NO.18)

[0112] a. PCR reaction uses a 50 μL system: 2 μL of primers, 2 μL of template, 10 μL of polymerase buffer, 1 μL of 10 M mdNTP, 1 μL of polymerase, 1 μL of ddH 2 O 32 μL. Cycling parameters: 96°C initial denaturation for 5 min; 95°C for 15 s, 58°C for 15 s, 72°C for about 30 s, 23 cycles, final extension at 72°C for 1 min;

[0113] b. Screen positive clones by bacterial solution PCR method, extract plasmids from the obtained positive bacterial solution at 37℃ and send them for sequencing;

[0114] c. Sequence the correct plasmid and perform double restriction digestion with ApaI-XhoI.

[0115] 2.1.5 Plasmid construction results

[0116] a. After PCR amplification of the single domain antibody target gene sequence, agarose gel electrophoresis was performed. The amplification results of the sample were as follows: Figure 1 .

[0117] b. Genetic bacterial liquid identification, after PCR amplification, agarose gel electrophoresis was performed. The amplification results of the sample are shown in the figure Figure 2 .

[0118] c. Empty vector digestion results: pET-22b(+) empty vector digestion was performed and then subjected to agarose gel electrophoresis. The results are as follows: Figure 3 .

[0119] d. Identification of recombinant cloned plasmids: The target gene obtained by PCR amplification was constructed into the pET-22b(+) vector, the plasmid was extracted, and the plasmid was digested with ApaI-XhoI and then subjected to agarose gel electrophoresis. The results were as follows: Figure 4 .

[0120] e. Plasmid map: The results are as follows Figure 5 .

[0121] d. Sequencing results: The sequencing primer was T7ter: TGCTAGTTATTGCTCAGCGG (SEQ ID NO.19), and the results were as follows Figure 6 .

[0122] 2.2 Expression identification, optimization and solubility analysis

[0123] a. Transform BL21(DE3) competent cells with plasmid pET-22b(+), invert and culture at 37℃ overnight. Select a single clone and culture in LB medium at 37℃ until the bacterial OD600 is 0.6-0.8, add IPTG to a final concentration of 0.5mM, culture at 37℃ for 4 hours, then centrifuge, collect the bacteria and prepare samples for SDS-PAGE and Western Blot analysis;

[0124] b. After the inoculated seed bacteria were cultured to a bacterial OD600 of 0.6-0.8, IPTG was added to the culture to a final concentration of 0.2 mM and 1 mM, respectively, and cultured at 37°C and 15°C at 220 rpm for 4 hours and 16 hours, respectively, to induce the expression of the fusion protein, and samples were prepared for SDS-PAGE analysis under each condition;

[0125] In the previous step, the bacterial suspensions of each condition were centrifuged to collect the bacteria, broken (Tris-NaCl buffer), and the supernatant precipitates were sampled and analyzed by SDS-PAGE.

[0126] 2.3 Amplification and purification

[0127] a. The optimal clone was cultured in LB medium at 37°C until OD 600 =0.6~0.8, induced at 15℃ for 16 hours and harvested;

[0128] b. Collect the bacteria by centrifugation, resuspend the bacteria, and disrupt them by ultrasonication;

[0129] c. Centrifuge and purify the supernatant by nickel column affinity chromatography. The buffer is as follows:

[0130] Equilibration buffer: "PBS-NaCl", pH 7.4

[0131] Washing buffer: "PBS-NaCl", pH 7.4 + 50 mM imidazole

[0132] Elution buffer: "PBS-NaCl", pH 7.4 + 500 mM imidazole

[0133] c. Prepare samples for SDS-PAGE analysis.

[0134] 2.4 Protein dialysis

[0135] The samples that meet the requirements were combined and dialyzed into PBS, pH 7.4, and then filtered for sterilization.

[0136] 2.5 Experimental Results

[0137] The results are as follows Figure 1-11 .

[0138] The results showed that the plasmid vector containing the single domain antibody gene sequence was successfully constructed. It is feasible to express single domain antibodies in prokaryotic systems, and sufficient amounts of high purity single domain antibodies can be purified from the supernatant after cell disruption.

[0139] Example 3 Expression of single domain antibodies in eukaryotic systems and purification thereof

[0140] 3.1 Cell transfection

[0141] The VHH-human Fc fusion protein plasmid was constructed, and the plasmid was transfected using CHO-S expression system transfection reagent, and the supernatant was collected for purification.

[0142] 3.2 Protein purification Mab Select Sure LX gravity column purification

[0143] a. After cell centrifugation, the culture supernatant was directly purified with Mab Select Sure LX. The filler was loaded into a gravity column tube with the following buffer:

[0144] Equilibration buffer: PBS pH 7.4

[0145] Washing buffer: PBS pH 7.4

[0146] Elution buffer: 0.1 M glycine, pH 3.5

[0147] b. Equilibrate with 20 column volumes of equilibration solution PBS, add the equilibrated filler to the culture medium supernatant, and incubate with rotation at 4°C for 1-1.5h;

[0148] c. Add the incubation product to the gravity column tube and collect the flow-through;

[0149] d. After loading, continue to wash with 20 times column volume of equilibrium buffer;

[0150] e. After the washing is completed, use elution buffer to elute and collect;

[0151] f. After elution, adjust the pH to neutral with 1M Tris-HCl, pH 7.4;

[0152] g. SDS-PAGE electrophoresis detection, ultrafiltration and exchange of liquid into PBS to determine the concentration and purity.

[0153] Example 4 ELISA to verify the ability of single domain antibodies to bind to different serotypes of AAV

[0154] 4.1 ELISA validation process

[0155] a. AAV2, AAV5, AAV6, and AAV8 were diluted with coating buffer and incubated at 4°C overnight;

[0156] b. Wash the plate 3 times with 200ul PBST (0.05% tween-20, pH 7.2);

[0157] c. Add 100ul / well 5% (v / v) skim milk powder and block at 37°C for 1 hour;

[0158] d. Wash the plate 3 times, add 100ul / well single domain antibody-human IgG Fc (2ug / ml) to the experimental group, and 100ul / well PBS to the blank control

[0159] (pH 7.2), incubated at 37°C for 1 h;

[0160] e. Wash the plate three times, add 100ul / well anti-human IgG1 Fc antibody, and incubate at 37°C for 1 hour;

[0161] f. Wash the plate 3 times and add 100ul / well TMB for color development;

[0162] g. Add 100ul / well stop solution;

[0163] h. Measure the absorbance at 450nm using an enzyme-labeled instrument.

[0164] 4.2 The single-domain antibody expressed in the eukaryotic system is fused with human IgG1 Fc. The following is the ELISA result

[0165] Table 1. OD450nm readings of single domain antibody and AAV2 ELISA binding activity verification

[0166]

[0167]

[0168] Table 2. OD450nm readings of single domain antibody and AAV5 ELISA binding activity verification

[0169] AAV5 vg / well Single domain antibodies Control group 1e+010 3.1272 0.2501 3.33e+009 2.4979 0.2931 1.11e+009 1.3628 0.2049 3.7e+008 0.6135 0.1537 1.23e+008 0.2569 0.0904

[0170] Table 3 OD450nm readings of single domain antibody and AAV6 ELISA binding activity verification

[0171] AAV6 vg / well Single domain antibodies Control group 1e+010 4 0.1649 3.33e+009 2.5534 0.1447 1.11e+009 1.4094 0.1469 3.7e+008 0.5703 0.1433 1.23e+008 0.2084 0.1296

[0172] Table 4 OD450nm readings of single domain antibody and AAV8 ELISA binding activity verification

[0173] AAV8 vg / well Single domain antibodies Control group 1e+010 4 0.0443 3.33e+009 2.0514 0.0512 1.11e+009 0.894 0.0472 3.7e+008 0.3211 0.05 1.23e+008 0.0842 0.0262

[0174] Combination Figure 12-15 As well as the above table, it can be seen that single-domain antibodies have strong binding ability with AAV2, AAV5, AAV6, and AAV8.

[0175] 4.3 Prokaryotic expression of single-domain antibodies and verification of their AAV binding activity by ELISA, with the detection antibody being anti-single-domain antibody-HRP antibody

[0176] a. AAV2, AAV5, AAV6, and AAV8 were diluted with coating buffer and incubated at 4°C overnight;

[0177] b. Wash the plate 3 times with 200ul PBST (0.05% tween-20, pH 7.2);

[0178] c. Add 100ul / well 5% (v / v) skim milk powder and block at 37°C for 1 hour;

[0179] d. Wash the plate three times, add 100ul / well single domain antibody (2ug / ml) to the experimental group and 100ul / well PBS (pH7.2) to the blank control, and incubate at 37°C for 1 hour;

[0180] e. Wash the plate three times, add 100ul / well anti-single domain antibody-HRP (1:5000), and incubate at 37°C for 1 hour;

[0181] f. Wash the plate 3 times and add 100ul / well TMB for color development;

[0182] g. Add 100ul / well stop solution;

[0183] h. Measure the absorbance at 450nm using an enzyme-labeled instrument.

[0184] Table 5. OD450nm readings for single domain antibody and AAV2 ELISA binding activity verification

[0185] AAV2 vg / well Single domain antibodies Control group 1e+010 3.6626 0.05299 3.33e+009 1.6421 0.05849 1.11e+009 0.9793 0.035 3.7e+008 0.6114 0.03929 1.23e+008 0.3885 0.0766

[0186] Table 6. OD450nm readings for single domain antibody and AAV5 ELISA binding activity verification

[0187]

[0188]

[0189] Table 8. OD450nm readings for single domain antibody and AAV8 ELISA binding activity verification

[0190] AAV8 vg / well Single domain antibodies Control group 1e+010 2.9156 0.0583 3.33e+009 1.7639 0.0533 1.11e+009 0.7865 0.0484 3.7e+008 0.2412 0.0466 1.23e+008 0.1252 0.0321

[0191] Combination Figure 16-19 , from the ELISA results of single-domain antibodies expressed in eukaryotic systems fused with human IgG1 Fc, AAV2, AAV5, AAV6 and AAV8 can all have strong binding ability with single-domain antibodies. Next, we used anti-single-domain antibody-HRP antibody to detect the binding activity of single-domain antibodies with different serotypes of AAV, and the results showed that single-domain antibodies have good binding activity with AAV2, AAV5, AAV6 and AAV8.

[0192] Example 5 Purification test of AAV stock solution by purification filler coupled with anti-AAV single domain antibody

[0193] We also coupled single-domain antibodies to microspheres to construct AAV affinity purification media and tested their purification ability.

[0194] AAV purification using single domain antibody affinity media, the experimental steps and results are as follows:

[0195] 5.1 Preparation of AAV samples

[0196] 5.1.1 Cultivation and transfection of packaging cell line 293T cells

[0197] a. Take 293T out of liquid nitrogen and place it in a 37°C water bath to dissolve it quickly;

[0198] b. Transfer the cell solution to a 15 mL centrifuge tube and add 1 mL of fresh complete medium. Mix by pipetting and centrifuge at 156 × g (1000 rpm) for 5 minutes. Discard the supernatant and add 1 mL of fresh complete medium to resuspend the cells.

[0199] c. Add the cell resuspension to a 100 mm culture dish. Add 9 mL of culture medium to each dish in advance. Mix well and place the dish at 37°C and 5% CO. 2 Culture in an incubator.

[0200] 5.1.2 Adeno-associated virus packaging

[0201] a. Extract the adeno-associated virus shuttle plasmid and its auxiliary packaging plasmid respectively to high purity and endotoxin-free for use;

[0202] b. When the cell density is 70-90%, transfect 293T cells. The plasmid transfection system is as follows:

[0203]

[0204]

[0205] c. Preheat DMEM (containing three antibodies) to 37°C, return the transfection reagent to room temperature, and mix the culture medium DMEM and pHelper evenly;

[0206] d. Add the reagent in the pHelper tube to the serotype centrifuge tube according to the amount required for each serotype, and then add the corresponding serotype plasmid amount and mix well;

[0207] e. Add the target plasmid and then the transfection reagent into the centrifuge tube and mix well with a pipette. Let it stand for 20 minutes and transfer it to a dish.

[0208] 5.1.3 Preparation of crude virus extract

[0209] a. Observe the fluorescence after transfection, add fresh culture medium once in the middle, digest the cells 72 hours after transfection, centrifuge at 3000rpm for 10 minutes, pour out the supernatant, add PBS to resuspend, and freeze-thaw the resuspended liquid three times in liquid nitrogen and 37℃ water bath, then centrifuge at 3000rpm for 10 minutes.

[0210] b. Take the supernatant, add 3 μL Benzonase enzyme (enzyme: PBS = 1:100), and incubate at 37°C for 1 hour to remove the cell genome and residual plasmid DNA in the virus solution;

[0211] c. Centrifuge at 3000 rpm and 4°C for 10 minutes. The titer of the AAV crude extract was measured and used in subsequent purification and verification experiments of single-domain antibody affinity microspheres.

[0212] 5.2 Purification of AAV using single domain antibody affinity purification media

[0213] a. 1 ml of single domain antibody affinity filler was loaded into the column, and the column was equilibrated for 3-5 CV with AAV binding buffer (PBS + 0.35 M NaCl + 0.01% F68, pH 7.2-7.4) on AKTA;

[0214] b. The prepared AAV crude extract (treated with universal enzyme, filtered through 0.45 μm after centrifugation, and 0.01% F68) was loaded at a loading flow rate of 0.8 ml / min;

[0215] c. After loading, wash with binding buffer until baseline equilibrium;

[0216] d. Elute with elution buffer (0.1 M glycine, pH 2.0 adjusted with hydrochloric acid, 0.01% F68, 2 mM magnesium chloride), and immediately add 1 M Tris at a ratio of 1:10 to neutralize the collected eluate;

[0217] e) Wash with elution buffer (0.1 M phosphoric acid + 0.01% F68) for 5CV, then wash with PBS (pH 7.2) for another 5CV, and finally rinse the single domain antibody with 20% ethanol and store it in 20% ethanol.

[0218] Table 11. Titers of each component detected by ddPCR after affinity purification of single domain antibody affinity medium for AAV2 dynamic load

[0219] AAV2 Titer Sample (VG) 5.72E+12 Eluent (VG) 5.19E+12 Recovery rate (%) 90.73

[0220] Table 12. Titers of each component detected by ddPCR after affinity purification of single domain antibody affinity medium for AAV5 dynamic load

[0221] AAV5 Titer Sample (VG) 3.36E+13 Eluent (VG) 2.63E+13 Recovery rate (%) 78.12

[0222] Table 13. Titers of each component detected by ddPCR after affinity purification of single domain antibody affinity medium for AAV8 dynamic load

[0223] AAV8 Titer Load crude extract (VG) 1.33E+13 Eluent (VG) 1.25E+13 Recovery rate (%) 93.67

[0224] Combination Figure 20-23 And Tables 11-13 show that agarose gel microspheres coupled with single domain antibodies can affinity purify adeno-associated viruses AAV2, AAV5, and AAV8, with recovery rates of 90.73%, 78.12%, and 93.67%, respectively.

[0225] Example 6 Mutant 1 amino acid sequence

[0226] Single domain antibody mutant 1 variable region sequence G30A (SEQ ID NO.20)

[0227] QVQLQESGGGLVQAGGSLRLSCAASGRTH A MYAMGWFRQAPGKEREFVAVQDLTASNTHYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMSGSYNSARDYDYWGQGTQVTVSS

[0228] The IMGT rule number

[0229] CDR1 sequence is GRTH A MYA (SEQ ID NO. 21)

[0230] The CDR2 sequence is QDLTASNT (SEQ ID NO. 22)

[0231] The CDR3 sequence is AAGPTIMSGSYNSARDYDY (SEQ ID NO. 23)

[0232] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 24)

[0233] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO. 25)

[0234] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO. 26)

[0235] FR4 sequence is WGQGTQVTVSS (SEQ ID NO. 27)

[0236] Example 7 Mutant 2 amino acid sequence

[0237] Single domain antibody mutant 2 variable region sequence S56T (SEQ ID NO.28)

[0238] QVQLQESGGGLVQAGGSLLRLSCAASGRTHGMYAMGWFRQAPGKEREFVAVQDLTA T N

[0239] THYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMSGSYNSARDYDY

[0240] WGQGTQVTVSS

[0241] The IMGT rule number

[0242] The CDR1 sequence is GRTHGMYA (SEQ ID NO. 29)

[0243] CDR2 sequence is QDLTA T NT (SEQ ID NO.30)

[0244] The CDR3 sequence is AAGPTIMSGSYNSARDYDY (SEQ ID NO. 31)

[0245] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 32)

[0246] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO. 33)

[0247] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO. 34)

[0248] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.35)

[0249] Example 8 Mutant 3 amino acid sequence

[0250] Single domain antibody mutant 3 variable region sequence G105A (SEQ ID NO.36)

[0251] QVQLQESGGGLVQAGGSLLRLSCAASGRTHGMYAMGWFRQAPGKEREFVAVQDLTASN

[0252] THYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMS A SYNSARDYDYWG

[0253] QGTQVTVSS

[0254] The IMGT rule number

[0255] The CDR1 sequence is GRTHGMYA (SEQ ID NO. 37)

[0256] The CDR2 sequence is QDLTASNT (SEQ ID NO. 38)

[0257] CDR3 sequence is AAGPTIMS A SYNSARDYDY (SEQ ID NO. 39)

[0258] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 40)

[0259] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO.41)

[0260] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO.42)

[0261] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.43)

[0262] Example 9 Mutant 4 amino acid sequence

[0263] Single domain antibody mutant 4 variable region sequence G30A / S56T / G105A (SEQ ID NO.44)

[0264] QVQLQESGGGLVQAGGSLRLSCAASGRTH A MYAMGWFRQAPGKEREFVAVQDLTA T NTHYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMS A SYNSARDYDYWGQGTQVTVSS

[0265] The IMGT rule number

[0266] CDR1 sequence is GRTH A MYA (SEQ ID NO.45)

[0267] CDR2 sequence is QDLTA T NT (SEQ ID NO.46)

[0268] CDR3 sequence is AAGPTIMS A SYNSARDYDY (SEQ ID NO. 47)

[0269] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 48)

[0270] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO. 49)

[0271] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO.50)

[0272] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.51)

[0273] Example 12 Ability of mutants 1-4 to bind to different serotypes of AAV

[0274] In order to verify the ability of different mutants to bind to different serotypes of AAV, we constructed and expressed the above mutants 1-4, and conducted the same experiment as the single domain antibody in Example 1, with the same operation method as described above. The specific results are as follows:

[0275] The quality inspection SDS-PAGE electrophoresis results after single domain antibody purification are as follows Figure 1-6 As shown:

[0276] Fig.24 . SDS-PAGE results of G30A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0277] Fig.25 . SDS-PAGE results of S56T protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0278] Fig.26 . SDS-PAGE results of G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0279] Fig. 27 . SDS-PAGE results of G30A / S56T / G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0280] It can be seen that all mutants were successfully expressed.

[0281] The results of ELISA experiments on the ability of single domain antibody mutants to bind to different serotypes of AAV are shown in the following figure and table:

[0282] Fig.28 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV2 ELISA.

[0283] Fig.29 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV5 ELISA.

[0284] Fig.30 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV6 ELISA.

[0285] Fig.31 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV8 ELISA.

[0286] Table 14. OD450nm readings of single domain antibody wild type and its mutants and AAV2 ELISA binding activity verification

[0287]

[0288] Table 15. OD450nm readings of single domain antibody wild type and its mutants and AAV5 ELISA binding activity verification

[0289]

[0290] Table 16. OD450nm readings of single domain antibody wild type and its mutants and AAV6 ELISA binding activity verification

[0291]

[0292] Table 17. OD450nm readings of single domain antibody wild type and its mutants and AAV8 ELISA binding activity verification

[0293]

[0294]

[0295] According to the results of ELISA, the single-domain antibodies and their mutants showed considerable activity in binding to AAV2, AAV5, and AAV6.

[0296] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limitations of the present invention. In addition, the various modifications listed herein and the variations of methods and compositions in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications obvious to those skilled in the art as described above to obtain the invention should be included within the scope of the present invention.

Claims

1. A single domain antibody, characterized in that The single domain antibody comprises CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 is as shown in SEQ ID NO: 2, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% identity in function; The amino acid sequence of the CDR2 is as shown in SEQ ID NO: 3, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity; The amino acid sequence of the CDR3 is shown in SEQ ID NO: 4, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity.

2. The single domain antibody according to claim 1, characterized in that: The single domain antibody also includes any one or more of the following technical features: a. The single-domain antibody further comprises a framework region FR1 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO: 5; b. The single domain antibody further comprises a framework region FR2 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO: 6; c. The single domain antibody further comprises a framework region FR3 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO: 7; d. The single domain antibody further comprises a framework region FR4 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO:

8.

3. The single domain antibody according to claim 1, characterized in that: The amino acid sequence of the single domain antibody is shown in SEQ ID NO.

1.

4. The single domain antibody according to claim 1, characterized in that: The single domain antibody further comprises any one of the following technical features: a. The amino acid sequence of the CDR1 is shown in SEQ ID NO: 21; b. The amino acid sequence of the CDR2 is shown in SEQ ID NO: 30; c. The amino acid sequence of the CDR3 is shown in SEQ ID NO: 39; d. The amino acid sequence of the CDR1 is shown in SEQ ID NO:45, the amino acid sequence of the CDR1 is shown in SEQ ID NO:46; the amino acid sequence of the CDR1 is shown in SEQ ID NO:

47.

5. A gene encoding the single domain antibody as claimed in claim 1.

6. The gene according to claim 5, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO.

16.

7. A carrier, characterized in that: The vector contains or has inserted therein the gene as claimed in claim 5.

8. A cell, characterized in that The cells contain the vector as claimed in claim 7.

9. Use of the single domain antibody according to any one of claims 1 to 5 for purifying AAV.

10. A filler for purifying AAV, characterized in that: The filler contains the above-mentioned single domain antibody.

11. The packing according to claim 10, characterized in that: The single domain antibody is coupled to microspheres.

Citation Information

Patent Citations

  • Nanometer antibody capable of being combined with multiple AAV serotypes and application thereof

    CN116199773A

  • Nanometer antibody capable of being combined with multiple AAV serotypes and application thereof

    CN116239679A

  • Preparation and application of human adeno-associated virus (AAV) single-domain antibody

    CN116396381A

  • Nanobody for purification of different AAVs at wide pH

    CN117186212A

Cited By

  • Compound that enhances cell infection of virus

    WO2026212017A1